等待开盘 02-13 09:30:00 美东时间
-3.550
-7.45%
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics"), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors,
01-06 05:03
Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.
01-06 00:00
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
制药企业Crinetics Pharmaceuticals(CRNX)早盘飙升26.6%,获得美国FDA对肢端肥大症治疗药物Palsonify的批准。批准基于成功的三期试验,产品计划于10月初上市。这标志着Crinetics在罕见病治疗领域的重要里程碑。 海量资讯、精准解读,尽在新浪财经APP 责任编辑:张俊 SF065
2025-09-26 22:57
Crinetics Pharmaceuticals will host its R&D Day event on June 26, 2025, in New York, discussing updates on its early-stage pipeline assets, portfolio strategy, and advancements in treating endocrine diseases.
2025-06-16 12:00
Crinetics Pharmaceuticals granted stock options and RSUs to 20 new non-executive employees under its 2021 Inducement Plan. Stock options total 74,000 shares with an exercise price of $33.08 and RSUs total 48,850, both vesting over four years. The awards align with Nasdaq Listing Rule 5635(c)(4) and are conditioned on continued employment.
2025-06-10 20:29
Crinetics Pharmaceuticals (CRNX) will participate in the Jefferies Global Healthcare Conference June 3-5, 2025 in New York. Their presentation is June 5 at 12:50 p.m. ET. The company focuses on developing novel therapeutics for endocrine diseases and tumors.
2025-05-23 12:00
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral,
2024-09-27 04:10
Cantor Fitzgerald analyst Josh Schimmer reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and maintains $90 price target.
2024-09-16 23:36